Wuhan Hiteck Biological Pharma Co.,Ltd (China)

Wuhan Hiteck Biological Pharma Co., Ltd is a high-tech biopharmaceutical company located in Wuhan, China. It was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on August 8, 2017 (stock abbreviation: Hiteck Bio, stock code: 300683). The company's main business includes the production and sales of biotechnology products, lyophilized powder injections, and import-export of products and technologies. Currently, the company holds 25 production licenses for biological products and chemical drugs. The company's campus covers an area of 138,000 square meters, with a building area of over 61,000 square meters. It has a production plant that meets the national Good Manufacturing Practice (GMP) standards, covering an area of over 14,800 square meters. The company has established a comprehensive quality management system and a well-functioning quality management department to ensure compliance with GMP requirements and optimize product quality. With over 1,000 employees, 76% of whom have a university degree or above, the company has also established collaborations with renowned academicians and professors. It has a core cultural system that fosters high-quality management and technical personnel with values of integrity, gratitude, professionalism, and progress. Wuhan Hiteck Biological Pharma Co., Ltd is recognized as a high-tech enterprise in Hubei Province. It has a post-doctoral workstation approved by the Ministry of Human Resources and Social Security, as well as the "Hubei Rare Disease Drug Engineering Technology Research Center" and "Hubei High-Tech Innovative Enterprise" approved by the provincial science and technology department. The company has established five basic technology platforms and a pilot base to promote the industrialization and efficient market transformation of related achievements. The company focuses on the research, development, and production of drugs in the field of neurology and oncology. It has already launched a Class I national biopharmaceutical, injection of recombinant human nerve growth factor (NGF), and completed the Phase III clinical unblinding for a Class I gene engineering biopharmaceutical, recombinant circular permuted TRAIL (CPT). The latter is currently in the preparation stage for production approval. Wuhan Hiteck Biological Pharma Co., Ltd adheres to the corporate mission of "respecting life, fearless innovation" and practices the corporate values of integrity, gratitude, professionalism, and progress. It aims to become an excellent innovative pharmaceutical company in China. The company plans to expand its presence in the fields of macromolecular drugs, small molecule drugs, and in vitro diagnostics, with a focus on serving patients, continuous innovation, and becoming an outstanding pharmaceutical enterprise group.